MA Star Ratings
Part C & Part D Star Ratings β Comprehensive Historical Reference, 2007β2027
Source: CMS Part C & D Star Ratings Technical Notes & Performance Data β’ Values Edge, LLC
Star Ratings Lifecycle & Timing
The Star Ratings program spans ~3 years from performance measurement through revenue impact. The Advance Notice and Final Rule occur the year after data collection, when CMS proposes how that performance data will be scored. The chart below uses the 2024β2026 cycle as a concrete example.
Performance Year (2024)
Full-year data collection across HEDIS clinical measures, CAHPS member surveys (spring), HOS outcomes, and CMS administrative claims. This is the year plans are actually measured on quality.
Advance Notice (Feb 2025)
CMS publishes proposed methodology for scoring the 2024 performance data. First signal of weight changes, measure additions/retirements, and cut point methodology for the upcoming Star Ratings.
Final Rule (Apr 2025)
Confirmed methodology becomes official. Weight changes, new measures, and retirements are locked in. Plans learn exactly how their 2024 performance data will be scored.
CMS User Call (Aug 2025)
Technical briefing where CMS presents implementation details, cut point results, and answers plan questions. Key intelligence event for quality and strategy teams.
Ratings Released (Oct 2025)
Star Ratings published on Medicare Plan Finder. Plans learn their ratings and QBP eligibility. Consumers see ratings during Open Enrollment (Oct 15 β Dec 7).
QBP Revenue (Jan 2026+)
Quality Bonus Payments flow based on published ratings. 4+ star plans receive 5% benchmark increase (10% in double-bonus urban counties). Revenue impact continues for 12+ months.
The 2-Year Lag
Performance measured in 2024 determines Star Ratings released in October 2025, which drive Quality Bonus Payments starting January 2026. This means today's operational decisions won't affect revenue for ~2 years. Plans must invest in quality improvement well ahead of when the financial impact materializes.
Note: NCQA HEDIS specification changes can shift measure definitions mid-cycle, meaning the goalposts can move even after a performance year begins.
Program Timeline
Measure Count Over Time
| Year | Part C | Part D | Shared | Total |
|---|---|---|---|---|
| 2027 | 32 | 13 | 3 | 42 |
| 2026 | 33 | 12 | 3 | 42 |
| 2024-25 | 30 | 12 | 3 | 39-42 |
| 2022-23 | 30-31 | 14-15 | 3 | 42-43 |
| 2019-21 | 32 | 14 | 3 | 43-46 |
| 2016-18 | 32-34 | 14-15 | 3 | 44-47 |
| 2011-15 | ~32-33 | ~14-15 | 3 | ~44-47 |
| 2009-10 | ~28-30 | ~14 | 3 | ~40-42 |
| 2008 | ~20 | ~18 | ~3 | ~35 |
| 2007 | 0 (Part D only) | ~18 | 0 | ~18 |
Data Sources
HEDIS
Healthcare Effectiveness Data & Information Set. Clinical quality measures defined by NCQA.
Collection: Plans submit data annually; NCQA audits.
Measures: Screenings, chronic disease mgmt, medication, follow-up measures
CAHPS
Consumer Assessment of Healthcare Providers & Systems. Member satisfaction surveys.
Collection: CMS-contracted vendors survey members MarβMay yearly.
Measures: Patient experience, access, customer service, plan ratings
CMS Admin
Claims, enrollment, complaints (CTM), appeals, disenrollment data.
Collection: Continuous collection from CMS systems.
Measures: Appeals timeliness, complaint rates, member retention, access
HOS
Health Outcomes Survey. Longitudinal survey of physical/mental health status.
Collection: Baseline at enrollment, follow-up 2 years later.
Measures: Improving/Maintaining Physical Health, Mental Health
PDE / IRE
Prescription Drug Event data and Independent Review Entity data.
Collection: Drug claims records + appeals data.
Measures: Medication adherence, drug pricing, drug safety
PQA
Pharmacy Quality Alliance. Drug safety and adherence measure specifications.
Collection: Calculated from PDE data using PQA specifications.
Measures: Adherence (diabetes, hypertension, cholesterol), statin use, high-risk meds